LA Funds | Early Stage Venture Capital
home,page,page-id-5,page-template,page-template-full_width,page-template-full_width-php,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-,vc_responsive
Addressing the needs and challenges of emerging technology through traditional early stage venture capital

About Us

Early stage venture capital is in its infancy in Louisiana. Historically early stage investing in Louisiana has been done by high net worth individuals but it is sporadic, not well organized and does not provide sufficient capital or resources to early stage companies. Out of state venture funds and Louisiana CAPCO’s provide large pools of capital to late stage companies requiring large equity and debt financing. As a result of this gap in financing, early stage high technology companies either do not get started, struggle for financing or move out of Louisiana.


Targeted investments, are companies developing commercially promising technologies with an emphasis on those originating in Louisiana Universities, Louisiana companies and companies relocating to Louisiana. The companies will be in life sciences, including: pharmaceuticals, biotechnology, agritechnology, information technology and other high technology opportunities that offer venture capital returns.


Closing the gap between
the hardships of investment and research


Louisiana Funds are an early stage venture capital funds focused on the identification of investment opportunities emanating from research universities and other organizations in the state of Louisiana.


Louisiana universities spend over $500 million annually on research in the areas of interest to Louisiana Funds.



Richard Babb

Managing Director

Mr. Babb has over 30 years of diverse business, accounting and financial management experience, having been a Manager with Ernst & Young’s Entrepreneurial Services Group handling various venture capital clients, having been the Chief Financial Officer for Medical Science Partners, a Harvard-affiliated life science venture capital fund and as the NASD Chief Compliance Officer, for Apeiron Partners LLC.

Richard holds a BS in Business Administration from American International College and is an inactive Certified Public Accountant, and has NASD licenses Series 7, 24, 28 & 63.


Joseph Lovett

Managing Director

Mr. Lovett has over 34 years of venture capital and operations experience in the healthcare areas of biotechnology, medical devices and equipment, diagnostics, imaging and services. Operations experience included increasingly responsible positions in marketing and general management at CR Bard, Mallinckrodt and Damon Biotech. Venture capital experience includes three venture capital funds (1988-2003) as general partner in affiliation with Harvard University managing $70,000,000 which resulted in 13 IPOs, 6 sales of private companies, 3 private companies. Mr. Lovett has a BA in economics from the University of Vermont and an MBA from California State Polytechnic University (Pomona).


Brain Vital Corporation

BrainVital Corporation is developing a neurostimulator for the treatment of chronic epilepsy.

CaloSyn Pharma, Inc.

Embera NeuroTherapeutics Inc.

A development stage, speciality pharmaceutical company that has been formed to develop and commercialize novel treatments of a broad range of addictions. The company will test and commercialize a patenet-pending combinational drug designed to treat a wide array of addictions by targeting specific brain functions that lead to cravings and relapse.

Esperance Pharmaceutical, Inc.

The Company develops unique products that aim to treat cancers of reproductive organs, especially metastatic breast cancer, by targeting hormone receptors found on tumor cells with a proprietary lytic peptide technology. A development-stage company with offices in Baton Rouge, Louisiana. Its research and development activities originated in the laboratories of Dr. William Hansel, Dr. Fred Enright, and Dr. Carola Leuschner, at the Pennington Biomedical Research Center, Louisiana State University, and the LSU AgCenter.

Infrastruct Security, Inc.

Infrastruct Security, Inc is a convergent security provider dedicated to ensuring our business clients are secure and ready to counter the unexpected. Infrastruct focus’s on select commercial and industrial customers in the Texas and Louisiana Gulf Coast region. Infrastruct is a full turn-key provider of one stop security solutions with local technical support and a sustained inventory. Infrastruct does everything in house, thus quotes are competitive and offer a higher degree of quality control and customer support responsiveness.

International Mezzo Technologies, Inc.

Mezzo is a spin-off of the MicroSystems Engineering Team Laboratory (µSET) at Louisiana State University, which over the years has attracted millions of dollars in federal, state, and industrial support for research and development of new micromanufacturing technology. Mezzo’s core focus is merging thermal science and micromachining technology to form revolutionary thermal systems. Applications for this technology include: high power electronics, cryocoolers, radar systems, directed energy weapons, turbo machinery, fuel cells, pumps, thermal management, power systems, chemical reactors, and many other products. In addition, Mezzo provides design analysis, prototyping, and production services for RF, microfluidic, optic, magneto, bio-analytical, and electronic devices.

NuPotential, Inc.

Oxus Medical, Inc.

Cardiac oximery technology for navigation to and through the cornonary sinus

Primorigen Biosciences, LLC

Developing research “tool kits” that will help scientists quickly develop therapies that can change one type of cell to another, such as brain, liver or skin cells. The new cells can be used to treat everything from diabetes and strokes to liver failure and burns. NuPotential is an early stage biotechnology company based in research facilities at the Louisiana Emerging Technology Center in Baton Rouge. Dr. Ken Eilersten, who holds a faculty appointment with the Pennington Biomedical Research Center, invented the company’s patent-pending technologies for cell reprogramming. The company has received nearly $1 million from the National Institutes of Health for its work.

Tesa Medical, Inc.


Your Name (required)

Your Email (required)


Your Message